European Antibiotics Market Size, Share, Trends, Growth and Forecast Report 2021-2027

Description

The global European Antibiotics market garnered revenue around USD 13,672.2 million in 2020 and projected to reach USD 14,630.7 million in 2027, with at a compound annual growth rate (CAGR) 2.9% throughout the estimate period from 2021 to 2027. Antibiotics are medicines that fight bacterial infections in people and animals. They work by killing the bacteria or by making it hard for the bacteria to grow and multiply.In addition, they are used to cure several diseases such as strep throat, urinary tract infections, sinus infections, pneumonia, skin infections, ear infections, and others. There are numerous ways of classifying antibiotics, however, the most common classification is based on their chemical structures, spectrum of activity, and mode of action. Currently, the demand for beta lactam and beta lactamase inhibitors class of antibiotics is high among healthcare providers.

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the European Antibiotics market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the European Antibiotics market growth.

The global European Antibiotics market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

The key players operating in the European antibiotics market include Abbott Laboratories, Abbvie Inc. (Allergan Plc.), Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Viatris Inc., Novartis International AG (Sandoz), Pfizer Inc., and Sanofi.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Class

·         Beta Lactam and Beta Lactamase Inhibitors

·         Penicillin

·         Cephalosporin

·         Carbapenem

·         Monobactam

·         Quinolone

·         Macrolide

·         Others

By Drug Origin

·         Natural

·         Semisynthetic

·         Synthetic

By Spectrum of Activity

·         Broad-spectrum Antibiotic

·         Narrow-spectrum Antibiotic

By Route of Administration

·         Oral

·         Intravenous

·         Others

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:

North America

United States

Canada

 

Europe

Germany

United Kingdom

Italy

France

Rest of EU

 

Asia Pacific

China

India

Japan

Southeast Asia

Rest of APAC

 

Central & South America 

Brazil 

Argentina

Rest of Central & South America 

 

Middle East and Africa

GCC

North Africa

South Africa

TABLE OF CONTENT

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global European Antibiotics Market, By Class

7.1.  European Antibiotics Market, by Class, 2020-2027

7.1.1.    Beta Lactam and Beta Lactamase Inhibitors

7.1.1.1.        Market Revenue and Forecast (2016-2027)

7.1.2.    Penicillin

7.1.2.1.        Market Revenue and Forecast (2016-2027)

7.1.3.    Cephalosporin

7.1.3.1.        Market Revenue and Forecast (2016-2027)

7.1.4.    Carbapenem

7.1.4.1.        Market Revenue and Forecast (2016-2027)

7.1.5.    Monobactam

7.1.5.1.        Market Revenue and Forecast (2016-2027)

7.1.6.    Quinolone

7.1.6.1.        Market Revenue and Forecast (2016-2027)

7.1.7.    Macrolide

7.1.7.1.        Market Revenue and Forecast (2016-2027)

7.1.8.    Others

7.1.8.1.        Market Revenue and Forecast (2016-2027)

Chapter 8.  Global European Antibiotics Market, By Drug Origin

8.1.  European Antibiotics Market, by Drug Origin, 2020-2027

8.1.1.    Natural

8.1.1.1.        Market Revenue and Forecast (2016-2027)

8.1.2.    Semisynthetic

8.1.2.1.        Market Revenue and Forecast (2016-2027)

8.1.3.    Synthetic

8.1.3.1.        Market Revenue and Forecast (2016-2027)

Chapter 9.  Global European Antibiotics Market, By Spectrum of Activity

9.1.  European Antibiotics Market, by Spectrum of Activity, 2020-2027

9.1.1.    Broad-spectrum Antibiotic

9.1.1.1.        Market Revenue and Forecast (2016-2027)

9.1.2.    Narrow-spectrum Antibiotic

9.1.2.1.        Market Revenue and Forecast (2016-2027)

Chapter 10.      Global European Antibiotics Market, By Route of Administration

10.1.        European Antibiotics Market, by Route of Administration, 2020-2027

10.1.1.  Oral

10.1.1.1.      Market Revenue and Forecast (2016-2027)

10.1.2.  Intravenous

10.1.2.1.      Market Revenue and Forecast (2016-2027)

10.1.3.  Others

10.1.3.1.      Market Revenue and Forecast (2016-2027)

Chapter 11.      Global European Antibiotics Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Class (2016-2027)

11.1.2.  Market Revenue and Forecast, by Drug Origin (2016-2027)

11.1.3.  Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.1.4.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Class (2016-2027)

11.1.5.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.1.5.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.1.5.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Class (2016-2027)

11.1.6.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.1.6.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.1.6.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Class (2016-2027)

11.2.2.  Market Revenue and Forecast, by Drug Origin (2016-2027)

11.2.3.  Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.2.4.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Class (2016-2027)

11.2.5.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.2.5.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.2.5.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Class(2016-2027)

11.2.6.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.2.6.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.2.6.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Class (2016-2027)

11.2.7.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.2.7.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.2.7.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Class (2016-2027)

11.2.8.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.2.8.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.2.8.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Class (2016-2027)

11.3.2.  Market Revenue and Forecast, by Drug Origin (2016-2027)

11.3.3.  Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.3.4.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Class (2016-2027)

11.3.5.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.3.5.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.3.5.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Class (2016-2027)

11.3.6.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.3.6.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.3.6.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Class (2016-2027)

11.3.7.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.3.7.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.3.7.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Class (2016-2027)

11.3.8.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.3.8.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.3.8.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Class (2016-2027)

11.4.2.  Market Revenue and Forecast, by Drug Origin (2016-2027)

11.4.3.  Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.4.4.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Class (2016-2027)

11.4.5.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.4.5.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.4.5.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Class (2016-2027)

11.4.6.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.4.6.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.4.6.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Class (2016-2027)

11.4.7.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.4.7.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.4.7.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Class (2016-2027)

11.4.8.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.4.8.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.4.8.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Class (2016-2027)

11.5.2.  Market Revenue and Forecast, by Drug Origin (2016-2027)

11.5.3.  Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.5.4.  Market Revenue and Forecast, by Route of Administration (2016-2027)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Class (2016-2027)

11.5.5.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.5.5.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.5.5.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Class (2016-2027)

11.5.6.2.      Market Revenue and Forecast, by Drug Origin (2016-2027)

11.5.6.3.      Market Revenue and Forecast, by Spectrum of Activity (2016-2027)

11.5.6.4.      Market Revenue and Forecast, by Route of Administration (2016-2027)

Chapter 12.  Company Profiles

12.1.              Abbott Laboratories

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              Abbvie Inc. (Allergan Plc.)

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              Bayer AG

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              F. Hoffmann-La Roche Ltd.

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              GlaxoSmithKline plc

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Merck & Co. Inc.

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Viatris Inc.

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Novartis International AG (Sandoz)

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Pfizer Inc.

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Sanofi.

12.10.1.               Company Overview

12.10.2.               Product Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

14.2.              Glossary of Terms

Choose License Type

Checkout Inquiry Sample